Aducanumab is a monoclonal antibody which has recently been licenced for use by the food and drug administration for treatment of patients with mild cognitive impairment due to Alzheimer's disease (AD) or mild AD dementia. Appropriate use criteria (AUC) for Aducanumab in clinical practice are available. We look to review patients in our specialist interdisciplinary cognitive service with positive cerebrospinal fluid (CSF) biomarkers for AD for their hypothetical eligibility for Aducanumab, or a similar anti-amyloid agent.

中文翻译：

---

爱尔兰专家认知服务中 Aducanumab 治疗的潜在资格——利用脑脊液生物标志物和适当的使用标准

Aducanumab 是一种单克隆抗体，最近被食品和药物管理局批准用于治疗由于阿尔茨海默病 (AD) 或轻度 AD 痴呆引起的轻度认知障碍患者。Aducanumab 在临床实践中的适当使用标准 (AUC) 是可用的。我们期待在我们的专家跨学科认知服务中审查患有 AD 脑脊液 (CSF) 生物标志物阳性的患者，以确定他们是否符合 Aducanumab 或类似的抗淀粉样蛋白药物的假设资格。